Article Text

Download PDFPDF
Assessing and measuring cognitive function in major depressive disorder
  1. Renee-Marie Ragguett1,
  2. Danielle S Cha1,2,
  3. Ron Kakar1,
  4. Joshua D Rosenblat1,3,
  5. Yena Lee1,
  6. Roger S McIntyre1,3,4
  1. 1Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada;
  2. 2Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada;
  3. 3Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada;
  4. 4Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr Roger S McIntyre, Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8; roger.mcintyre{at}


Cognitive dysfunction is a major component of major depressive disorder (MDD). No ‘gold-standard’ tool exists for the assessment of cognitive dysfunction for adults with MDD. The use of measurement-based care to improve treatment outcomes invites the need for a systematic screening, evaluation and measurement tool. The aim herein was to provide a succinct summary of literature documenting clinical implication of cognitive dysfunction in MDD, and a review of available screening, diagnostic and measurement tools for cognitive dysfunction in MDD is provided. We also take the opportunity to introduce a screening tool (ie, the THINC-it tool) targeted at addressing the unmet needs. We found that there are limitations to the current measurement scales; for example, many are not targeted for MDD and not all digitally available tests are free of charge. Furthermore, the spectrum of cognitive dysfunction in MDD is poorly represented by the existing tests and as such, there is a lack of sensitivity in the ability to screen a patient with MDD for a cognitive dysfunction. Recognising and addressing the limitations in the current screening techniques for cognitive dysfunction as well as being presented with the current tools available provides the ability to perform an educated cognitive screening for a patient with MDD.

Statistics from


  • Competing interests RSM has the following disclosures: Advisory board/researcher, consulting fees and speaker fees, no equity; AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Pfizer, Merck, Sunovion, Otsuka, Takeda and Allergan. Researcher, speaker fees, no equity; Janssen-Ortho. Researcher, funding for research, no equity; Shire.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.